Teliso-V
telisotuzumab vedotin
FILED
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$1500M
Formulations[]
Mechanism: c-Met-targeting ADC
Expert: Antibody-drug conjugate targeting c-Met receptor with MMAE payload for c-Met overexpressing NSCLC.
Everyday: A targeted drug that delivers chemotherapy to lung cancer cells with specific mutations.
Targets: ["MET"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| c-Met+ NSCLC | FILED | TELISO-V Ph3 | [] |
Upcoming Catalysts (1)
Teliso-V - NSCLC - Accelerated Approval
2026
Notes
c-Met targeting ADC for EGFR-WT, c-Met+ NSCLC. Filed for 2L+ NSCLC. Potential first-in-class in this biomarker segment.
Data from Supabase · Updated 2026-03-24